Marie Lafleur is a seasoned intellectual property litigator. She regularly appears before the courts in proceedings under the Patented Medicines (Notice of Compliance) Regulations and litigation concerning pharmaceutical patent infringement or invalidity. Her expertise encompasses biologicals and biosimilars.
Marie has represented numerous companies in proceedings to prevent the Minister of Health from issuing Notices of Compliance that would allow generic versions of patented drugs to be sold, including citalopram, escitalopram, doxylamine/pyridoxine, cyclosporin, omeprazole, diltiazem, divalproex and terazosin.
She has also successfully filed numerous applications to add or remove patents from the Health Canada register. She was involved in many applications for judicial review of various decisions by provincial and federal health ministers.
Marie’s expertise covers every extraordinary remedy, particularly seizures before judgment and injunctions, and she fully masters the range of alternative dispute resolution mechanisms available.